

# Contents

---

<i>Foreword</i> .....	(v)
<i>Preface</i> .....	(vii)

## Chapter – 1.1

### Documentation in Pharmaceutical Industry

1.1.1 Master Formula Record- Definition.....	1
1.1.2 Master Formula Record .....	1
1.1.3 MFR-Product Details .....	1
1.1.4 Procedure to Prepare a Master Formula Record .....	3
1.1.5 SOP for Preparation of the Master Formula Record.....	3
1.1.6 Steps to Prepare a Master Formula Record.....	3
1.1.7 The First Page of both the Sections Shall have Following Details.....	3
1.1.8 Batch Formula should have the following columns.....	4
1.1.9 At the End of Every Important Stage, include a Statement of the Yield with the Acceptable Limits .....	5
1.1.10 The Packaging Part of MFR.....	5
<i>References</i> .....	6

## Chapter – 1.2

### Drug Master File (DMF)

1.2.1 Table of Contents .....	7
1.2.2 Guideline for Drug Master Files .....	8
<i>References</i> .....	19

## Chapter – 1.3

### Distribution of Records

1.3.1 Introduction.....	20
1.3.2 Why Distribution of Records is Necessary? .....	20
1.3.3 Objectives .....	21
1.3.4 Documentation in Pharmaceutical Industry .....	22
<i>References</i> .....	28

## **Chapter – 1.4**

### **Generic Drugs Product Development**

1.4.1 Generic Drug.....	30
1.4.2 What are Generic Drugs?.....	30
1.4.3 When Generic Drug Marketed? .....	30
1.4.4 Where are they Available? .....	31
1.4.5 Product Development.....	31
<i>References</i> .....	36

## **Chapter – 1.5**

### **Hatch-Waxman Act**

1.5.1 Objectives of the Act.....	37
1.5.2 Drug Approval .....	37
1.5.3 New Drug Exclusivity.....	39
1.5.4 ANDA Exclusivity .....	41
1.5.5 Patent Term Extension .....	41
1.5.6 Patent Litigation Under The Hatch-Waxman Act.....	41
1.5.7 Benefits for Branded Manufacturers.....	42
1.5.8 Conclusion .....	42
<i>References</i> .....	43

## **Chapter – 1.6**

### **Code of Federal Regulations (CFR)<sup>[1-4]</sup>**

1.6.1 What is CFR? .....	44
1.6.2 History of CFR.....	45
1.6.3 CFR Title 21 .....	45
1.6.4 Chapter I.....	45
1.6.5 Chapter II .....	46
1.6.6 CFR in Modern Times .....	47
1.6.7 Research Tools in CFR .....	47
1.6.8 Conclusion .....	47
<i>References</i> .....	48

## Chapter – 1.7

### **Drug Product Performance, *IN VITRO***

1.7.1 Introduction.....	49
1.7.2 Importance of <i>In vitro</i> Drug Product Characterization .....	49
1.7.3 Factors Affecting <i>In vitro</i> Drug Product Dissolution.....	51
1.7.4 Applications of <i>In vitro</i> Dissolution.....	60
1.7.5 Waivers of <i>In vivo</i> Bioequivalence Requirements .....	61
1.7.6 Summary .....	63
<i>References</i> .....	64

## Chapter – 1.8

### **ANDA Regulatory Approval Process**

1.8.1 ANDA .....	67
1.8.2 Basic Generic Drug Requirements.....	67
1.8.3 Goal of ANDA .....	68
1.8.4 Generic Drug Approval.....	68
1.8.5 Indispensability Ground for Generics .....	68
1.8.6 Hatch-Waxman Act.....	69
1.8.7 General Provisions of the Act .....	69
1.8.8 Recent additions to the Hatch-Waxman Act.....	69
1.8.9 Modules in a CTD.....	74
1.8.10 ANDA CONTENTS [Table 1] .....	74
1.8.11 NDA CONTENTS [Table 2] .....	75
1.8.12 IND CONTENTS [Table 3].....	75
1.8.13 Broad Outline for ANDA.....	75
1.8.14 Information required for Filing ANDA.....	76
1.8.15 Recommendations for e CTD .....	76
1.8.16 First-Time Generic Drug Approvals - July 2011 [Table 4] .....	76
1.8.17 Patent Certification condition for ANDA .....	77
1.8.18 Patent Challenge Successful – Award of 180-Day .....	77
1.8.19 Orphan Drug Exclusivity (ODE) .....	77
<i>References</i> .....	86

## Chapter – 1.9

### Regulatory Requirements for Product Approval

1.9.1 Introduction.....	87
1.9.2 Drug Approval Process in United States.....	88
1.9.3 Drug Approval Process in Europe .....	94
1.9.4 Drug Approval Process in India.....	98
1.9.5 Discussion .....	101
1.9.6 Conclusion .....	102
<i>References</i> .....	102

## Chapter – 1.10

### SUPAC

1.10.1 What is SUPAC ?.....	104
1.10.2 SUPAC.....	104
1.10.3 SUPAC Guidelines [figure 1] .....	105
1.10.4 Level of Changes .....	105
1.10.5 SUPAC IR.....	105
1.10.6 Changes in Components and Composition .....	106
1.10.7 Changes to Level 1.....	106
1.10.8 Level 2 Changes.....	106
1.10.9 Level 3 Changes.....	106
1.10.10 Site Change .....	107
1.10.11 Change Package Size .....	107
1.10.12 Production Changes .....	108
1.10.13 SUPAC-MR .....	109
1.10.14 Site Changes.....	110
1.10.15 Modifications of Working Tools.....	111
1.10.16 Change in Production Process.....	111
<i>References</i> .....	112

## Chapter – 1.11

### Outsourcing BA & BE to CRO

1.11.1 Introduction.....	113
1.11.2 What is Outsourcing ?.....	113
1.11.3 Reasons to Outsource.....	113

1.11.4 Clinical Outsourcing and CRO Market Development .....	114
1.11.5 Functional Service Delivery.....	114
1.11.6 Real Proof in the World .....	115
1.11.7 e-buy .....	116
1.11.8 Bioavailability and Life Balance.....	116
1.11.9 Outsource Standardized Services for BA-BE Courses Biological analysis studies .....	117
1.11.10 Common Services Outsourced for BA-BE Courses .....	117
1.11.11 Advantages [ figure 2].....	117
1.11.12 Key Elements for Success.....	118
1.11.13 Consider Time/Cost .....	118
1.11.14 Medical Site Qualification/Audit-Medical Site Assessment....	118
1.11.15 CRO (Contract Research Organization).....	119
1.11.16 The Problem of Outsourcing.....	119
1.11.17 Summary .....	120
1.11.18 Tips for Safe Outsourcing.....	120
<i>References</i> .....	120

## Chapter – 1.12

### **Regulatory Requirements for Registration of API in US and EU**

1.12.1 Introduction.....	121
1.12.2 Regulatory Authority [7-10] .....	122
1.12.3 Objectives .....	124
1.12.4 Methodology [14-22].....	124
1.12.5 Discussion .....	126
1.12.6 API Registration in the European Union .....	134
1.12.7 Decentralized Procedure[40,41][FIGURE 3].....	136
1.12.8 Mutual-Recognition Procedure[FIGURE 4].....	136
1.12.9 Registration of API in EU .....	137
1.12.10 ASMF dossier [48,49].....	140
1.12.11 Certification of Suitability .....	141
1.12.12 Quality Requirements .....	142
1.12.13 Conclusion .....	142
<i>References</i> .....	142

## Chapter – 1.13

### Biologics

1.13.1	Introduction.....	148
1.13.2	Comparison between Biologics & Chemical Drug [Table 2] .....	150
1.13.3	Regulatory Authority for Biologics .....	150
1.13.4	Development and Approval Process.....	151
1.13.5	Biologics License Application .....	151
1.13.6	BLA Review Process .....	155
1.13.7	License Application .....	155
1.13.8	Collection and Submission of BLA .....	156
	<i>References</i> .....	156

## Chapter – 1.14

### U.S Registration for Foreign Drugs

1.14.1	Introduction.....	157
1.14.2	Regulatory Structure .....	158
1.14.3	US Food and Medical Administration .....	158
1.14.4	International Conference on Harmonization (ICH) .....	158
1.14.5	Possible Recession .....	158
1.14.6	Selection of Investigator/Site .....	160
1.14.7	Drug-Drug Interactions.....	160
1.14.8	Problems of Patients.....	160
1.14.9	Comparator and Dose Selection.....	161
1.14.10	Data Interruption .....	161
1.14.11	Design .....	161
	<i>References</i> .....	161

## Chapter – 1.15

### Bioequivalence and Drug Product Assessment

1.15.1	Introduction.....	162
1.15.2	Objectives .....	162
1.15.3	Subject.....	162
1.15.4	Requirements .....	163

1.15.5 Types.....	163
1.15.6 Requirements for <i>In Vivo</i> Courses .....	163
1.15.7 Statistical Analysis of Bio-equilibrium Data .....	163
1.15.8 Design and Evaluation of Bioequivalence Studies .....	164
1.15.9 Type of Design.....	164
1.15.10 Disadvantages .....	164
1.15.11 Advantages.....	164
1.15.12 Repeated Measured, Cross Over, Carry Over Design.....	165
1.15.13 Crossover Parallel Design.....	165
1.15.14 Crossover Studies.....	165
1.15.15 Randomized Complete Block Design of Six Subjects Receiving Four Treatments .....	165
1.15.16 Replicated Cross Over Design .....	166
1.15.17 Latin Square Cross Over Design for a Bioequivalence Study of the Three Drug Products in Six Human Volunteers .....	166
1.15.18 Types of Evidence.....	166
1.15.19 Type of Evidence to Establish Bioequivalence.....	167
1.15.20 Evaluation of Data .....	167
1.15.21 Dosage form Performance .....	167
1.15.22 BCS Classifying.....	168
<i>Web References</i> .....	168

## **Chapter – 1.16**

### **Post Marketing Surveillance**

1.16.1 Phases of Clinical Trials .....	169
1.16.2 Introduction.....	169
1.16.3 Post-Marketing Surveillance.....	169
1.16.4 History.....	170
1.16.5 Sources of PMS Information.....	170
1.16.6 What are the Benefits of a PMS System? .....	170
1.16.7 Machines that can abuse the Device .....	171
1.16.8 Evaluation .....	171
1.16.9 Why do we need Post-Marketing Surveillance? .....	171
1.16.10 Vision for Post-Marketing Tracking .....	171

1.16.11 Post-marketing Monitoring Opportunity.....	172
1.16.12 Practical Features of PMS.....	172
1.16.13 About PMS Process .....	172
1.16.14 PMS Reporting.....	172
1.16.15 Monitoring System.....	172
1.16.16 Manufacturer PMS System .....	173
1.16.17 Summary .....	174
<i>References</i> .....	174

## Chapter – 2.1

### Chemistry, Manufacturing and Controls (CMC)

2.1.1 Chemistry, Manufacturing and Controls (CMC) .....	175
2.1.2 Importance .....	186
2.1.3 What are the CMC Regulatory Issues? .....	186
2.1.4 CMC Regulatory Affairs (CMC-RA) .....	187
2.1.5 Regulatory Dossiers and its Contents .....	188
2.1.6 CMC Modules of Regulatory Dossier.....	189
2.1.7 Guidance used to Build Quality Section .....	195
2.1.8 Drug Ingredient (API) and Complete Dosage Form .....	195
2.1.9 Most Important CMC Problem .....	196
2.1.10 CMC Regulatory Issues .....	196
2.1.11 CMC Future .....	197
2.1.12 CVM CMC Guidelines .....	198
2.1.13 CMC Guidance Documents Applicable to Minor Use or Minor Species (MUMS) .....	203
<i>References</i> .....	205

## Chapter – 2.2

### CTD and E CTD

2.2.1 CTD and its Organisations.....	207
2.2.2 e CTD.....	212
<i>References</i> .....	222



## **Chapter – 2.3**

### **ICH Guidelines**

2.3.1 Introduction.....	223
2.3.2 ICH Objectives.....	223
2.3.3 ICH Location .....	223
2.3.4 Purpose of ICH.....	223
2.3.5 ICH Members.....	224
2.3.6 ICH System.....	224
2.3.7 ICH Coordinator .....	224
2.3.8 ICH Secretariat.....	225
2.3.9 ICH Working Group .....	225
2.3.10 ICH Operation.....	225
2.3.11 Stages of the ICH Process.....	225
2.3.12 Guidelines [figure 1].....	226
<i>References</i> .....	244

## **Chapter – 2.4**

### **Regulatory Requirement of EU, MHRA and TGA**

2.4.1 European Union .....	245
2.4.2 MHRA.....	248
2.4.3 TGA .....	250
2.4.4 Regulatory Requirements in Row Countries.....	252
<i>References</i> .....	253

## **Chapter – 3.1**

### **Investigational Medicinal Product Dossier (IMOD)**

3.1.1 European Medicines Agency (EMA).....	255
3.1.2 History.....	255
3.1.3 Drug Approval Process .....	256
3.1.4 Application for Clinical Screening.....	256
3.1.5 Investigational Medical Product Dossier .....	256
3.1.6 Introduction.....	257
3.1.7 IMPD: Content.....	257
3.1.8 Requirement of IMPD.....	257

3.1.9 What is an IMPD?.....	258
3.1.10 Characterisation .....	263
3.1.11 Active Control.....	263
3.1.12 Reference Levels or Building Materials .....	267
3.1.13 Container Closure Plan .....	267
3.1.14 Stability .....	267
3.1.15 Investigative Drug Product Testing .....	269
3.1.16 Appendices (A) .....	275
3.1.17 Guidance and Legal Basis.....	278
<i>References</i> .....	278

## Chapter – 3.2

### Investigator's Brochure

3.2.1 Introduction.....	279
3.2.2 Purpose.....	279
3.2.3 Investigators's Brouchure .....	279
3.2.4 Contents IB .....	280
<i>References</i> .....	283

## Chapter – 4.1

### Development of Clinical Trial Protocol

4.1.1 What is Protocol?.....	285
4.1.2 Phase II, A Randomized, Duplicate Study, Controlled By Placebo Tests for TJ301 (FE 999301) Injections for Patients With Active Ulcerative Colitis .....	288
4.1.3 Objectives of Test and Conclusion .....	290
4.1.4 Overall Design .....	292
4.1.5 Security Review Committee .....	292
4.1.6 Discussion of Trail Design Blinding.....	292
4.1.7 How to Include?.....	292
4.1.8 How to Assign Patients to Treatment Groups?.....	294
4.1.9 Data Handling .....	294
4.1.10 Changes in the Conduct of the Trial .....	294
4.1.11 Moral Responsibilities and Administrative Organizations ....	295
<i>References</i> .....	296

**Chapter – 4.2**

**Institutional Review Board (IRB)**

4.2.1	Composition, Processes, and Function.....	298
4.2.2	Categories of Released Research .....	300
4.2.3	Research Categories that can be Reviewed with Quick Procedures .....	301
4.2.4	Protection of Human Subjects.....	303
4.2.5	Documents for IRB/IEC.....	304
4.2.6	Protocol Review, Investigator Handbook, and Informed Consent.....	305
4.2.7	Protocol Review .....	306
4.2.8	Background .....	306
4.2.9	Main Impact Parameters .....	307
4.2.10	Eligibility Limit.....	307
4.2.11	Intervention Studies and Methods.....	308
4.2.12	Device Risks .....	309
4.2.13	Risks Associated with the Procedure .....	310
4.2.14	Process .....	311
4.2.15	Special Concerns with Life Banks .....	312
4.2.16	Protocol Elements and Tissue Banks [table 2].....	313
4.2.17	Investigator Brochure.....	314
4.2.18	Informed Consent.....	314
4.2.19	Qualifications of Investigator and Inquiry Committee .....	315
4.2.20	Risk-Benefit Analysis .....	316
4.2.21	Requirements for Approval of Research.....	317
4.2.22	Continuing Studies .....	321
4.2.23	Final Thoughts .....	322
	<i>References</i> .....	322

**Chapter – 4.3**

**Regulatory Requirements in Clinical Trails**

4.3.1	Introduction.....	326
4.3.2	Discussion .....	327
4.3.3	Conclusion .....	335
	<i>References</i> .....	336

## Chapter – 4.4

### Safety Monitoring and Reporting on Clinical Trails

4.4.1 Investigational Medicinal Product (IMP) Trails <sub>[1-5]</sub> .....	339
4.4.2 Investigational Medical Devices (IMD) Trials <sub>[1,2]</sub> .....	349
<i>References</i> .....	358

## Chapter – 4.5

### Health Insurance and Portability and Liability Act

4.5.1 What is HIPAA? .....	359
4.5.2 HIPAA Overview .....	364
4.5.3 Summary .....	367
<i>References</i> .....	368

## Chapter – 4.6

### Informed Consent Process and Procedures

4.6.1 Definition .....	369
4.6.2 Informed Consent Guidelines .....	369
4.6.3 Information Comprehension Voluntariness [Figure 1] .....	369
4.6.4 Approval Process .....	370
4.6.5 Approval Process Plan .....	370
4.6.6 Who can Sign the Informed Consent Form? .....	370
4.6.7 Informed Consent Form Elements .....	371
4.6.8 ICF Component .....	371
<i>References</i> .....	372

## Chapter – 4.7

### Pharmacovigilance

4.7.1 Introduction .....	373
4.7.2 Purpose and Objectives of Medicinal Awareness .....	373
4.7.3 How Pharmacovigilance works? [figure 1] .....	374
4.7.4 Adverse Drug Reactions Classifications [table 1] .....	374
4.7.5 Side Effect .....	374
4.7.6 Phases of Product Development [Table 2] .....	375

4.7.7	Pharmacovigilance and India .....	375
4.7.8	Who Should Report Safety Data? .....	375
4.7.9	What to Report? .....	376
4.7.10	Four Common Drug Banned in other Countries but not in India.....	376
4.7.11	Importance of Pharmacovigilance.....	377
4.7.12	Partners in Pharmacovigilance.....	377
4.7.13	Pharmacovigilance in Drug Regulation .....	377
4.7.14	THE Rapid .....	377
4.7.15	1964: U. K. starts “Yellow Card” System.....	378
4.7.16	At the Level of Clinicians . . . . .	378
4.7.17	Drug Alert Leaflets .....	378
4.7.18	Conclusion .....	379
	<i>References</i> .....	379